FrancophonIA/ELRC3.0 huggingface dataset:
English: No dose adjustment of Dafiro HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m
Estonian: Kerge kuni mõõduka neerukahjustusega patsientidel (GFR ≥30 ml/min/1,73 m 2) ei ole vaja Dafiro
English: How to store Dafiro HCT
Estonian: Kuidas Dafiro HCT'd säilitada
English: • fever (pyrexia)
Estonian: • palavik (püreksia)
English: • anxiety
Estonian: • ärevus
English: Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
Estonian: Dafiro HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid on kollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VEL”.
English: Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Estonian: Dafiro HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VFL”.
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides.
Estonian: AKE inhibiitorite, angiotensiin II retseptori antagonistide, sealhulgas valsartaani, või tiasiidide samaaegsel kasutamisel liitiumiga on täheldatud seerumi liitiumisisalduse pöörduvat suurenemist ning sellega kaasnevat toksilisust.
English: Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus
Estonian: Naha erütematoosluupuse taolised reaktsioonid, naha erütematoosluupuse reaktiveerumine
English: • facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
Estonian: • lööve näol, liigesvalu, lihaskahjustus, palavik (erütematoosne luupus)
English: EU/1/09/574/043 280 film-coated tablets
Estonian: EU/1/09/574/043 280 õhukese polümeerikattega tabletti
English: Dafiro HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide.
Estonian: 65-aastased ja vanemad inimesed võivad Dafiro HCT'd kasutada samades annustes nagu teised täiskasvanud ning samal viisil nagu nad on siiamaani võtnud kolme toimeainet, milleks on amlodipiin, valsartaan ja hüdroklorotiasiid.. Eakatel patsientidel, iseäranis neil, kes võtavad Dafiro HCT maksimaalset annust (10 mg/320 mg/25 mg), tuleks regulaarselt mõõta vererõhku.
English: EU/1/09/574/031 280 film-coated tablets
Estonian: EU/1/09/574/031 280 õhukese polümeerikattega tabletti
English: EU/1/09/574/055 280 film-coated tablets
Estonian: EU/1/09/574/055 280 õhukese polümeerikattega tabletti
English: EU/1/09/574/042 98 film-coated tablets
Estonian: EU/1/09/574/042 98 õhukese polümeerikattega tabletti
English: • medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);
Estonian: (MSPVA'd), sh selektiivsed tsüklooksügenaas-2 (COX-2) inhibiitorid;
English: • vision disorder
Estonian: • nägemise halvenemine
English: EU/1/09/574/006 98 film-coated tablets
Estonian: EU/1/09/574/006 98 õhukese polümeerikattega tabletti
English: Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Dafiro HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/574/026 28 film-coated tablets
Estonian: EU/1/09/574/026 28 õhukese polümeerikattega tabletti
English: EU/1/09/574/005 90 film-coated tablets
Estonian: EU/1/09/574/005 90 õhukese polümeerikattega tabletti
English: EU/1/09/574/007 280 film-coated tablets
Estonian: EU/1/09/574/007 280 õhukese polümeerikattega tabletti
English: EU/1/09/574/004 56 film-coated tablets
Estonian: EU/1/09/574/004 56 õhukese polümeerikattega tabletti
English: EU/1/09/574/018 98 film-coated tablets
Estonian: EU/1/09/574/018 98 õhukese polümeerikattega tabletti
English: EU/1/09/574/040 56 film-coated tablets
Estonian: EU/1/09/574/040 56 õhukese polümeerikattega tabletti
English: EU/1/09/574/019 280 film-coated tablets
Estonian: EU/1/09/574/019 280 õhukese polümeerikattega tabletti
English: • visual impairment
Estonian: • kehakaalu langus
English: EU/1/09/574/041 90 film-coated tablets
Estonian: EU/1/09/574/041 90 õhukese polümeerikattega tabletti
English: EU/1/09/574/001 14 film-coated tablets
Estonian: EU/1/09/574/001 14 õhukese polümeerikattega tabletti
English: Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Estonian: Dafiro HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid on kahvatukollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VDL”.
English: EU/1/09/574/038 28 film-coated tablets
Estonian: EU/1/09/574/038 28 õhukese polümeerikattega tabletti
English: Pollakiuria
Estonian: Jäsemevalu
English: EU/1/09/574/049 14 film-coated tablets
Estonian: EU/1/09/574/049 14 õhukese polümeerikattega tabletti
English: EU/1/09/574/016 56 film-coated tablets
Estonian: EU/1/09/574/016 56 õhukese polümeerikattega tabletti
English: EU/1/09/574/054 98 film-coated tablets
Estonian: EU/1/09/574/054 98 õhukese polümeerikattega tabletti
English: Dafiro 10 mg/320 mg/25 mg film-coated tablets The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Dafiro HCT 10 mg/320 mg/25 mg õhukese polümeerikattega tabletid Dafiro HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/574/030 98 film-coated tablets
Estonian: EU/1/09/574/030 98 õhukese polümeerikattega tabletti
English: EU/1/09/574/029 90 film-coated tablets
Estonian: EU/1/09/574/029 90 õhukese polümeerikattega tabletti
English: (haemolytic anaemia)
Estonian: (antibiootikumid);
English: EU/1/09/574/015 30 film-coated tablets
Estonian: EU/1/09/574/015 30 õhukese polümeerikattega tabletti
English: EU/1/09/574/027 30 film-coated tablets
Estonian: EU/1/09/574/027 30 õhukese polümeerikattega tabletti
English: EU/1/09/574/052 56 film-coated tablets
Estonian: EU/1/09/574/052 56 õhukese polümeerikattega tabletti
English: Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets
Estonian: Dafiro HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets
Estonian: Dafiro HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid
English: EU/1/09/574/053 90 film-coated tablets
Estonian: EU/1/09/574/053 90 õhukese polümeerikattega tabletti
English: EU/1/09/574/025 14 film-coated tablets
Estonian: EU/1/09/574/025 14 õhukese polümeerikattega tabletti
English: • muscle spasm
Estonian: • neerukahjustus
English: EU/1/09/574/002 28 film-coated tablets
Estonian: EU/1/09/574/002 28 õhukese polümeerikattega tabletti
English: The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
Estonian: Teised koostisosad on mikrokristalne tselluloos; krospovidoon (tüüp A); kolloidne veevaba ränidioksiid; magneesiumstearaat; hüpromelloos (asenduse tüüp 2910 (3 mPa.s)), makrogool 4000, talk, titaandioksiid (E171), kollane raudoksiid (E172), punane raudoksiid (E172).
English: EU/1/09/574/014 28 film-coated tablets
Estonian: EU/1/09/574/014 28 õhukese polümeerikattega tabletti
English: Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets
Estonian: Dafiro HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: • disorder in passing urine
Estonian: • urineerimishäired
English: EU/1/09/574/037 14 film-coated tablets
Estonian: EU/1/09/574/037 14 õhukese polümeerikattega tabletti
English: EU/1/09/574/003 30 film-coated tablets
Estonian: EU/1/09/574/003 30 õhukese polümeerikattega tabletti
English: Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
Estonian: Dafiro HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid on pruunikaskollased, ovaalsed tabletid, mille ühel poolel on kiri „NVR” ja teisel „VHL”.
English: EU/1/09/574/039 30 film-coated tablets
Estonian: EU/1/09/574/039 30 õhukese polümeerikattega tabletti
English: EU/1/09/574/017 90 film-coated tablets
Estonian: EU/1/09/574/017 90 õhukese polümeerikattega tabletti
English: EU/1/09/574/050 28 film-coated tablets
Estonian: EU/1/09/574/050 28 õhukese polümeerikattega tabletti
English: EU/1/09/574/051 30 film-coated tablets
Estonian: EU/1/09/574/051 30 õhukese polümeerikattega tabletti
English: • sensitivity to light
Estonian: • valgustundlikkus
English: Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets
Estonian: Dafiro HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid
English: Uncommon (may affect up to 1 in 100 people):
Estonian: Aeg-ajalt (võib esineda kuni 1 inimesel 100-st):
English: EU/1/09/574/044 56 x 1 film-coated tablet (unit dose) EU/1/09/574/045 98 x 1 film-coated tablet (unit dose) EU/1/09/574/046 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/574/044 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/045 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/046 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/574/056 56 x 1 film-coated tablet (unit dose) EU/1/09/574/057 98 x 1 film-coated tablet (unit dose) EU/1/09/574/058 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/574/056 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/057 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/058 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Dafiro HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid Dafiro HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/574/008 56 x 1 film-coated tablet (unit dose) EU/1/09/574/009 98 x 1 film-coated tablet (unit dose) EU/1/09/574/010 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/574/008 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/009 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/010 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: EU/1/09/574/032 56 x 1 film-coated tablet (unit dose) EU/1/09/574/033 98 x 1 film-coated tablet (unit dose) EU/1/09/574/034 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/574/032 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/033 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/034 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Dafiro HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Dafiro HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Dafiro HCT 5 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: Gynaecomastia
Estonian: Pollakisuuria
English: • inflammation of blood vessels
Estonian: • vere kaaliumisisalduse langus
English: Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Dafiro HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid Dafiro HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Dafiro HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171).
Estonian: Teised koostisosad on mikrokristalne tselluloos; krospovidoon (tüüp A); kolloidne veevaba ränidioksiid; magneesiumstearaat; hüpromelloos (asenduse tüüp 2910 (3 mPa.s)), makrogool 4000, talk, titaandioksiid (E171).
English: Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Estonian: Dafiro HCT 10 mg/160 mg/25 mg õhukese polümeerikattega tabletid Dafiro HCT toimeained on amlodipiin (amlodipiinbesülaadina), valsartaan ja hüdroklorotiasiid.
English: EU/1/09/574/013 14 film-coated tablets
Estonian: EU/1/09/574/013 14 õhukese polümeerikattega tabletti
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan and 25 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 320 mg valsartaani (valsartanum) ja 25 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Dafiro HCT 5 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: • fainting
Estonian: • minestamine
English: Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Estonian: Dafiro HCT 10 mg/160 mg/12,5 mg õhukese polümeerikattega tabletid amlodipinum/valsartanum/hydrochlorothiazidum
English: EU/1/09/574/020 56 x 1 film-coated tablet (unit dose) EU/1/09/574/021 98 x 1 film-coated tablet (unit dose) EU/1/09/574/022 280 x 1 film-coated tablet (unit dose)
Estonian: EU/1/09/574/020 56 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/021 98 x 1 õhukese polümeerikattega tablett (üksikannus) EU/1/09/574/022 280 x 1 õhukese polümeerikattega tablett (üksikannus)
English: The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous, magnesium stearate, hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, yellow iron oxide (E172).
Estonian: Teised koostisosad on mikrokristalne tselluloos; krospovidoon (tüüp A); kolloidne veevaba ränidioksiid; magneesiumstearaat; hüpromelloos (asenduse tüüp 2910 (3 mPa.s)), makrogool 4000, talk, kollane raudoksiid (E172).
English: EU/1/09/574/028 56 film-coated tablets
Estonian: EU/1/09/574/028 56 õhukese polümeerikattega tabletti
English: • increased sensitivity of skin to sun
Estonian: • naha suurenenud valgustundlikkus
English: The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous, magnesium stearate, hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).
Estonian: Teised koostisosad on mikrokristalne tselluloos; krospovidoon (tüüp A); kolloidne veevaba ränidioksiid; magneesiumstearaat; hüpromelloos (asenduse tüüp 2910 (3 mPa.s)), makrogool 4000, talk, titaandioksiid (E171), kollane raudoksiid (E172).
English: EU/1/09/574/036 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/035 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/036 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/035 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: EU/1/09/574/048 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/047 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/048 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/047 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 12,5 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: EU/1/09/574/060 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/059 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/060 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/059 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 5 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 25 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.
Estonian: Iga õhukese polümeerikattega tablett sisaldab 10 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 25 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: EU/1/09/574/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/024 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/023 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: • tiredness
Estonian: • unetus
English: Rare (may affect up to 1 in 1,000 people):
Estonian: Harv (võib esineda kuni 1 inimesel 1000-st):
English: • swelling of the gums
Estonian: • turse (ödeem) pahkluude ümber
English: EU/1/09/574/012 280 film-coated tablets (multipack, 20 cartons of 14 tablets) EU/1/09/574/011 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)
Estonian: EU/1/09/569/012 280 õhukese polümeerikattega tabletti (hulgipakend, 20 karpi, igaühes 14 tabletti) EU/1/09/569/011 280 õhukese polümeerikattega tabletti (hulgipakend, 4 karpi, igaühes 70 tabletti) (üheannuseline)
English: • weight decrease
Estonian: • valutundlikkuse vähenemine
English: • altered bowel habits
Estonian: • naha värvuse muutused
English: Tabulated list of adverse reactions
Estonian: Kõrvaltoimete loetelu tabeli kujul
English: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 5 mg amlodipiini (amlodipinum) (amlodipiinbesülaadina), 160 mg valsartaani (valsartanum) ja 12,5 mg hüdroklorotiasiidi (hydrochlorothiazidum).
English: Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend
English: It is given once every three weeks as an infusion lasting 10 minutes.
Estonian: Seda manustatakse iga kolme nädala järel 10-minutilise infusioonina.
English: The full EPAR and risk management plan summary for Pemetrexed Lilly can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pemetrexed Lilly kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Pemetrexed Lilly is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pemetrexed Lilly võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pemetrexed Lilly?
Estonian: Mis meetmed võetakse, et tagada Pemetrexed Lilly ohutu ja efektiivne kasutamine?
English: This results in the division of cancer cells being reduced, while normal cells are only slightly affected.
Estonian: Selle tulemusena väheneb vähirakkude pooldumine ja normaalseid rakke kahjustatakse vähe.
English: The Committee recommended that Pemetrexed Lilly be approved for use in the EU.
Estonian: Komitee soovitas Pemetrexed Lilly kasutamise Euroopa Liidus heaks kiita.
English: As a result, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from dividing and multiplying.
Estonian: Selle tulemusena aeglustab pemetrekseedi aktiivne vorm DNA ja RNA moodustumist ja takistab rakkude pooldumist.
English: • malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
Estonian: • pleura maliigne mesotelioom (kopsukelme vähk, mida tavaliselt põhjustab kokkupuude asbestiga), kusjuures Pemetrexed Lillyt kasutatakse koos tsisplatiiniga patsientidel, kes ei ole varem keemiaravi saanud ja kelle vähkkasvajat ei saa eemaldada kirurgiliselt;
English: No additional studies were needed as Pemetrexed Lilly is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Pemetrexed Lilly on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: What is Pemetrexed Lilly and what is it used for?
Estonian: Mis on Pemetrexed Lilly ja milleks seda kasutatakse?
English: Because Pemetrexed Lilly is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pemetrexed Lilly on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Lilly has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pemetrexed Lilly sarnane toime ravimiga Alimta.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Lilly.
Estonian: Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb Pemetrexed Lilly ravi ajal süstida B12-vitamiini.
English: In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides' (the building blocks of DNA and RNA, the genetic material of cells).
Estonian: Pemetrekseed muundub organismis aine aktiivseks vormiks, mis blokeerib nukleotiidide (rakkude geneetilise materjali DNA ja RNA komponendid) tekkes osalevate ensüümide toimet.
English: This means that Pemetrexed Lilly is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Pemetrexed Lilly on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Lilly, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pemetrexed Lilly omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Pemetrexed Lilly is a cancer medicine used to treat two types of lung cancer:
Estonian: Pemetrexed Lilly on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks: